These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36679933)
1. A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis to Avert Rabies Deaths in School-Aged Children in India. Royal A; John D; Bharti O; Tanwar R; Bhagat DK; Padmawati RS; Chaudhary V; Umapathi R; Bhadola P; Utarini A Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679933 [TBL] [Abstract][Full Text] [Related]
2. Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines. Quiambao B; Varghese L; Demarteau N; Sengson RF; Javier J; Mukherjee P; Manio LC; Preiss S Int J Infect Dis; 2020 Aug; 97():38-46. PubMed ID: 32450291 [TBL] [Abstract][Full Text] [Related]
3. Rabies vaccination strategies in the Netherlands in 2018: a cost evaluation. Suijkerbuijk AW; Mangen MJ; Haverkate MR; Luppino FS; Bantjes SE; Visser LG; Swaan CM; Ruijs WL; Over EA Euro Surveill; 2020 Sep; 25(38):. PubMed ID: 32975187 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of rabies post exposure prophylaxis in Iran. Hatam N; Esmaelzade F; Mirahmadizadeh A; Keshavarz K; Rajabi A; Afsar Kazerooni P; Ataollahi M J Res Health Sci; 2014; 14(2):122-7. PubMed ID: 24728746 [TBL] [Abstract][Full Text] [Related]
5. An economic case study of the control of dog-mediated rabies by an animal welfare organisation in Jaipur, India. Larkins AJ; Reece JF; Shaw APM; Thrusfield MV Prev Vet Med; 2020 Oct; 183():105120. PubMed ID: 32890917 [TBL] [Abstract][Full Text] [Related]
6. One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety. Quiambao BP; Lim JG; Bosch Castells V; Augard C; Petit C; Bravo C; Delore V; Houillon G Vaccine; 2022 Aug; 40(36):5347-5355. PubMed ID: 35933278 [TBL] [Abstract][Full Text] [Related]
7. Is Pre-Exposure Prophylaxis a Cost-Effective Intervention to Avert Rabies Deaths among School-Aged Children in India? Comment on Royal et al. A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis to Avert Rabies Deaths in School-Aged Children in India. Kapur V Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992260 [TBL] [Abstract][Full Text] [Related]
8. Reply to Kapur, V. Is Pre-Exposure Prophylaxis a Cost-Effective Intervention to Avert Rabies Deaths among School-Aged Children in India? Comment on "Royal et al. A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis to Avert Rabies Deaths in School-Aged Children in India. Royal A; John D; Bharti O; Tanwar R; Bhagat DK; Padmawati RS; Chaudhary V; Umapathi R; Bhadola P; Utarini A Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112719 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness modelling studies of all preventive measures against rabies: A systematic review. Anothaisintawee T; Julienne Genuino A; Thavorncharoensap M; Youngkong S; Rattanavipapong W; Meeyai A; Chaikledkaew U Vaccine; 2019 Oct; 37 Suppl 1():A146-A153. PubMed ID: 30554795 [TBL] [Abstract][Full Text] [Related]
10. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. Ginsberg GM; Chemtob D BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis. Tantawichien T; Sibunruang S; Tantawichien T; Angsanakul J; Benjavongkulchai M; Limsuwan K; Udomchaisakul P; Khomvilai S; Sitprija V Expert Rev Vaccines; 2014 Dec; 13(12):1593-601. PubMed ID: 25315021 [TBL] [Abstract][Full Text] [Related]
13. The Route of Administration of Rabies Vaccines: Comparing the Data. Briggs DJ; Moore SM Viruses; 2021 Jun; 13(7):. PubMed ID: 34199111 [TBL] [Abstract][Full Text] [Related]
14. Should travellers to rabies-endemic countries be pre-exposure vaccinated? An assessment of post-exposure prophylaxis and pre-exposure prophylaxis given to Danes travelling to rabies-endemic countries 2000-12. Christiansen AH; Rodriguez AB; Nielsen J; Cowan SA J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27147729 [TBL] [Abstract][Full Text] [Related]
15. Modelling to inform prophylaxis regimens to prevent human rabies. Hampson K; Abela-Ridder B; Bharti O; Knopf L; Léchenne M; Mindekem R; Tarantola A; Zinsstag J; Trotter C Vaccine; 2019 Oct; 37 Suppl 1(Suppl 1):A166-A173. PubMed ID: 30528846 [TBL] [Abstract][Full Text] [Related]
16. Scaling up antivenom for snakebite envenoming in the Brazilian Amazon: a cost-effectiveness analysis. Zimmerman A; Monteiro W; Nickenig Vissoci JR; Smith ER; Rocha T; Sachett J; Wen FH; Staton C; Gerardo CJ; Ogbuoji O Lancet Reg Health Am; 2024 Jan; 29():100651. PubMed ID: 38124996 [TBL] [Abstract][Full Text] [Related]
17. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis. Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of rabies post-exposure prophylaxis in the context of very low rabies risk: A decision-tree model based on the experience of France. Ribadeau Dumas F; N'Diaye DS; Paireau J; Gautret P; Bourhy H; Le Pen C; Yazdanpanah Y Vaccine; 2015 May; 33(20):2367-78. PubMed ID: 25797366 [TBL] [Abstract][Full Text] [Related]
19. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734 [TBL] [Abstract][Full Text] [Related]
20. Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania. Shim E; Hampson K; Cleaveland S; Galvani AP Vaccine; 2009 Nov; 27(51):7167-72. PubMed ID: 19925948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]